Vehicle, Cenegermin clinical trials

Randomized, Double-Blinded, Vehicle-Controlled, Parallel Group, Adaptive Proof-of-concept, Dose-selecting Phase 2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Intranasal Cenegermin (recombinant human Nerve Growth Factor [rhNGF]) in Adult Participants with subacute moderate to severe Traumatic Brain Injury (TBI).

This study is testing a new nasal spray called Cenegermin for adults who have recently had a moderate to severe head injury. We want to see if it's safe and how well people tolerate it, looking for any side effects over six months.